with interferon-a or with radiotherapy is limited to multifocal skin lesions (3) .
Rituximab, a genetically engineered anti-CD20 monoclonal antibody, already approved for the treatment of non-DISCUSSION Hodgkin's lymphomas (3, 4) , has been recently used in primary cutaneous B-cell lymphoma (5) .
Marginal zone B-cell lymphoma, characterized clinically by The recent observation of a patient aOE ected by a primary solitary or cluster erythematous papules, nodules or plaques, multifocal B-cell cutaneous lymphoma, marginal zone type, usually shows an indolent clinical behaviour, slow evolution prompted us to use Rituximab as a single agent, with and good prognosis (3). satisfactory results.
Rituximab is a monoclonal antibody directed against the B-cell speci c antigen CD20, which is a 297 amino acid phosphoprotein expressed on pro-B-cells and B-cells, and CASE REPORT overexpressed on malignant B-cells. CD20 antigen seems to in vitro (7) . In most patients, this treatment is well tolerated the subcutaneous tissue (Fig. 2a) . Small lymphocytes and monowithout serious systemic adverse eOE ects. Temporary peripheral cytoid cells were the main neoplastic component. Immunohistoblood B-cell depletion may occur, but it has not been associated chemical staining revealed positivity for CD20 (Fig. 2b, d ) and for l-immunoglobulin light chains (Fig. 2c) , whereas k-light chains, CD5
with immunode ciency or signi cant changes in immunoand CD10 were negative. A scattered CD3 positivity was also observed globulin G levels (8) . Recent data demonstrate complete or within and around the neoplastic in ltrate. Staging of the patient (TC more often partial remission in half of the patients with total body, bone marrow biopsy, laboratory ndings) showed no systemic relapsed low-grade lymphomas. The follow-up abnormalities and anti-Borrelia burgdorferi antibodies were absent.
showed a median remission of about 1 year (9).
The clinical picture, the immunohistological ndings and the absence of extracutaneous localizations were indicative of a primary cutaneous
We used Rituximab as a rst-choice agent for the treatment B-cell lymphoma of marginal zone type. The multifocal localization of a disseminated cutaneous marginal zone lymphoma with no additional chemotherapy, and observed a good therapeutic response and no signi cant side-eOE ects. Furthermore, we observed the downregulation of CD20 antigen on neoplastic cells at the end of therapy. The loss of CD20 expression is a phenomenon already reported in the literature, which seems to occur only rarely (10 ) and may decrease the e cacy of this treatment. However, Treon et al. reported that interferon-c at pharmacologically achievable concentrations induced CD20 expression on B-lymphocytes (11). It will be interesting to observe the clinical response to an interferon-c/Rituximab combined treatment in patients with CD20+ lymphoproliferative diseases. 
